FDA Eases Biosimilar Testing Rules to Speed Approvals and Cut Drug Development Costs

The U.S. Food and Drug Administration is moving to simplify parts of the biosimilar approval process, a regulatory shift that could lower development costs, speed market entry, and expand competition for some of the most expensive medicines used in the U.S. health system. Reuters reported on March 9, 2026 that the agency issued draft guidance aimed at reducing certain testing requirements for biosimilar developers, including some pharmacokinetic studies, when adequate scientific evidence already exists. The change is part of a broader FDA effort to modernize biosimilar regulation and reduce barriers that manufacturers say have slowed competition in biologics, a category that includes many therapies used in oncology, immunology, and chronic disease management.

What happened is fairly specific but commercially important. Reuters reported that the FDA’s draft guidance recommends streamlining certain pharmacokinetic, or PK, studies that evaluate how the body interacts with a drug, and that the agency believes the change could cut those study costs by as much as 50%, or around $20 million per biosimilar program. Reuters also reported that companies may in some cases use clinical data from a comparable version of the reference biologic approved outside the United States, which could eliminate the need for an extra three-way comparison study involving the proposed biosimilar, the U.S.-licensed reference product, and the foreign comparator. In the same Reuters report, the FDA also said it was withdrawing a 2015 guidance document that no longer reflects the agency’s current thinking after years of reviewing biosimilar applications.

Why this matters to the healthcare market is straightforward: biologics consume a disproportionately large share of U.S. drug spending, and biosimilars have not scaled as quickly as generic drugs. Reuters said biologics account for about 5% of prescriptions but 51% of overall drug spending. That same Reuters report said the FDA has approved 82 biosimilars in the United States. The FDA’s own biosimilar policy materials, however, have repeatedly emphasized that the market remains underdeveloped relative to the size of the opportunity. On its March 10, 2026 guidance update page, the agency listed two new biosimilar guidance documents released that week, including a final “Questions and Answers on Biosimilar Development and the BPCI Act” and a draft “New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4).” That timing suggests the March 9 Reuters report was not an isolated policy item but part of a broader FDA push to refresh the regulatory framework around biosimilar development.

The market implication is that the FDA is continuing to move away from one-size-fits-all clinical requirements and toward a more evidence-based development model. That trend was visible in an earlier FDA announcement from October 29, 2025, when the agency said comparative efficacy studies often take one to three years, cost about $24 million on average, and generally have lower sensitivity than analytical assessments. In that same FDA announcement, the agency said expensive biologic medicines account for 51% of total drug spending while FDA-approved biosimilars remain a small fraction of the market. Taken together with the new March 2026 actions, the direction is clear: the FDA is trying to remove testing it sees as redundant while preserving the core scientific standard for biosimilarity. For manufacturers, that can improve return on investment; for payers and providers, it raises the possibility of more entrants and more pricing pressure in categories where biologic spending remains stubbornly high.

Who is impacted most immediately? First are biosimilar developers, contract research organizations, and regulatory affairs teams, because streamlined PK and comparator requirements can change development budgets, study design, and go-to-market timelines. Second are health plans, pharmacy benefit managers, and hospital formularies that are looking for additional leverage against high-cost biologic therapies. Third are providers and patients, especially in therapeutic areas where biologics are common and affordability remains a barrier. Although this item is more pharmaceutical than surgical, it still matters to the broader healthcare supply chain because biologics influence specialty pharmacy budgets, infusion economics, oncology service lines, and payer-provider contracting decisions. When biosimilar pathways become more predictable, purchasing behavior can gradually shift from single-brand dependence toward multi-supplier competition.

Industry groups welcomed the move quickly. On March 10, 2026, the Association for Accessible Medicines and its Biosimilars Council said the FDA’s updated guidance removes redundant PK testing requirements where scientifically rigorous data already exists and allows developers to cite comparative data not limited to U.S. sources. The group said the guidance also removes the need for duplicative comparative studies. John Murphy III, president and CEO of the Association for Accessible Medicines, said the FDA was “continuing to trust the science” and that the modernization would help developers bring high-quality biosimilars to patients more quickly. The group also argued that over the next decade more than 100 biologic medicines will lose patent protection, while roughly 90% currently have no biosimilar in development. That makes regulatory efficiency a major commercial issue, not a procedural one.

FDA Commissioner Marty Makary framed the policy direction clearly in the Reuters report, saying, “Streamlining biosimilar development reflects our ongoing commitment to lowering drug costs for everyday Americans.” Strategically, that quote matters because it shows the agency is linking scientific modernization directly to competition and affordability. The deeper market insight is that the FDA appears increasingly willing to rely on accumulated regulatory experience and analytical evidence rather than preserve legacy study requirements by default. For biosimilar manufacturers, that should improve the economics of entry. For incumbents in branded biologics, it increases the medium-term risk of more organized price competition in therapeutic classes that have remained relatively insulated.

The bottom line is that this is a meaningful regulatory development for the U.S. drug market. It does not guarantee a surge of immediate biosimilar launches, and draft guidance still leaves room for comment and interpretation. But it does move the FDA closer to a model in which unnecessary testing is stripped out, development costs come down, and biosimilar programs become easier to justify financially. That is the kind of regulatory adjustment that can reshape investment decisions across the biologics market over time.

Review current biologic exposure across high-spend categories, watch the FDA’s biosimilar guidance docket for implementation details, and assess which upcoming loss-of-exclusivity products could become more commercially attractive under a lower-cost development model.